CSL Bulk Human Coagulation Factor VIII 500 IU (100 IU/mL) / von Willebrand factor 1200 IU powder for injection vial

Nazione: Australia

Lingua: inglese

Fonte: Department of Health (Therapeutic Goods Administration)

Principio attivo:

Von willebrand factor, Quantity: 1200 IU; Factor VIII, Quantity: 500 IU

Commercializzato da:

CSL Behring Australia Pty Ltd

INN (Nome Internazionale):

Factor VIII,Von willebrand factor

Forma farmaceutica:

Injection, powder for

Composizione:

Excipient Ingredients: sucrose; trometamol; sodium chloride; Albumin; sodium citrate dihydrate; calcium chloride dihydrate

Via di somministrazione:

Intravenous

Indicazioni terapeutiche:

von Willebrand disease (VWD) - Treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated. Haemophilia A (congenital FVIII deficiency) - Prophylaxis and treatment of bleeding in patients with haemophilia A.

Dettagli prodotto:

Visual Identification: A white or pale yellow, hygroscopic powder or friable solid; Container Type: Vial; Container Life Time: 3 Years; Container Temperature: Store below 25 degrees Celsius

Stato dell'autorizzazione:

Licence status A

Data dell'autorizzazione:

2013-09-02